US prostate cancer trial starts for EDAP's HIFU (high intensity focused ultrasound) therapy:
This article was originally published in Clinica
Representing efforts by EDAP TMS to take its ultrasound-based treatment for prostate cancer to the US market, a 12-centre, 240-patient trial of the technology has begun at Duke University Medical Center, in Durham, North Carolina. Researchers are testing the use of the Lyon, France-based firm's high intensity focused ultrasound (HIFU) technique, Ablatherm, as the initial treatment in men with newly-diagnosed, localised prostate cancer. The study will compare the technique with cryotherapy and patients will be monitored over the course of two years. The trial is sponsored by HealthTronics, which in 2004 agreed to distribute Ablatherm in the US. Ablatherm is already widely used in Europe, EDAP noted.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.